Positron emission tomography/computerized tomography in the evaluation of primary non-Hodgkin’s lymphoma of prostate

Bo Pan, Jian-Kui Han, Shi-Cun Wang, Ao Xu

Bo Pan, Jian-Kui Han, PET/CT Center, Qilu Hospital, the First Affiliated Hospital of Shandong University, Jinan 250012, Shandong Province, China
Bo Pan, Shi-Cun Wang, PET/CT Center, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei 23001, Anhui Province, China
Ao Xu, Department of Pathology, Affiliated Anhui Provincial Hospital of Anhui Medical University, Hefei 23001, Anhui Province, China

Author contributions: Pan B reviewed the literature, collected and compiled the PET/CT pictures, and prepared the manuscript; Wang SC revised the manuscript; Xu A provided and compiled the pathological images; and Han JK proposed the topic, revised the manuscript and contacted the target journal for publication.

Correspondence to: Dr. Jian-Kui Han, PET/CT Center, Qilu Hospital, the First Affiliated Hospital of Shandong University, No. 107, Cultural West Road, Jinan 250012, Shandong Province, China. jkhan@sdu.edu.cn Telephone: +86-531-82169661 Fax: +86-531-82169661 Received: April 24, 2013 Revised: June 8, 2013 Accepted: July 12, 2013 Published online: October 21, 2013

Abstract

Primary malignant lymphoma of the prostate is exceedingly rare. Here we report a case of a 65-year-old man who presented with increased urinary frequency, urinary urgency, and urinary incontinence for two years. Benign prostatic hyper trophy was suspected at primary impression. Ultrasound revealed a hypoechoic lesion of the prostate. The total serum prostate-specific antigen was within normal range. Positron emission tomography/computerized tomography (PET/CT) showed a hypermetabolic prostatic lesion. Prostate biopsy was consistent with a non-germinat center diffuse large B cell lymphoma. There was complete remission of the prostatic lesion following six cycles of chemotherapy as shown on the second PET/CT imaging. 18F-fluoro-deoxy glucose PET/CT is not only a complement to conventional imaging, but also plays a significant role in the diagnosis and evaluation of treatment response of prostatic lymphoma.

Key words: Fluoro-Deoxy-Glucose; Positron emission tomography/computerized tomography; Non-Hodgkin’s lymphoma; Prostatic lymphoma; Evaluation

Core tip: Primary prostatic lymphoma is extremely rare. There is no consensus on the primary prostatic lymphoma management. We report a case of primary diffuse large B cell lymphoma of the prostate incidentally found by 18F-fluoro-deoxy glucose (FDG) positron emission tomography/computerized tomography (PET/CT), and finally diagnosed by histopathological examination. 18F-FDG PET/CT is not only a complement to the conventional imaging studies, but also plays a significant role in the diagnosis and treatment of prostatic lymphoma.

INTRODUCTION

Primary prostatic lymphoma is extremely rare, to the best of our knowledge, less than 200 cases have been described in the world literature so far, mostly as single case reports, and a few as large-series studies. It constitutes 0.09% of prostate neoplasms and 0.1% of all non-Hodgkin lymphomas. The most common pathological
type is diffuse large B cell lymphoma (DLBCL). Because of unspecific clinical symptoms including increased urinary frequency, urinary urgency, occasional hematuria and acute urinary retention, primary prostatic lymphoma is easily misdiagnosed as benign prostatic hyperplasia or prostatitis, especially in elderly men, and it has a poor prognosis. Serum prostate-specific antigen (PSA) level is usually within normal limits in most patients. Due to the small number of patients reported, there is no consensus on the primary prostatic lymphoma management, including radiotherapy, chemotherapy and radical prostatectomy or combined strategies.

Here we report a case of primary DLBCL of the prostate incidentally found by 18F-fluoro-deoxy glucose (FDG) positron emission tomography/computerized tomography (PET/CT), and finally diagnosed by histopathological examination.

**CASE REPORT**

A 65-year-old man suffered from increased urinary frequency, urinary urgency, occasional nocturia for two years. Because of his age and symptoms presenting as benign prostate hyperplasia, he did not take it seriously until the symptoms were aggravating. On examination, the prostate was palpable with degree II of hypertrophy, the median sulcus was shallow, and there was no hepatosplenomegaly. Laboratory findings including blood count, liver and renal function were all normal. Chest X-ray revealed no abnormalities. Serology for human immunodeficiency virus, hepatitis B, and hepatitis C was negative. Tumor markers like alpha-fetoprotein, carcino-embryonic antigen and total PSA were within normal limits. Ultrasound revealed prostatic hyperplasia and a hypoechoic lesion measuring 3.1 cm × 3.5 cm in size in the right lobe, and the nature of hypoechoic lesion was unidentified. Ultrasound-guided puncture was suggested. The patient was referred for a whole body PET/CT study to identify whether other sites were involved. He was injected with 9.8 millieicuries of 18F-FDG and underwent a whole body scan with a dedicated PET/CT scanner. Except a nodal FDG uptake in the prostate gland with the maximum standardized uptake value (SUVmax) of 12.7 (Figure 1A and B), all appeared unremarkable. In order to establish the diagnosis, ultrasound-guided transrectal puncture was performed. Biopsy specimens were composed of colorectal mucosal epithelium and aggregated lymphocytes. Immunohistochemical examination demonstrated that CD20 (+), CD79a (+), Pax5 (+), BCL-6 (+), mum-1 (+), and Ki-67 (+, 60%) were positive and CD10 (-), vim (+/-), CD3 (-), CD45RO (-), CD30 (-), CX (-), PSA (-), syn (-), and CGA (-) were negative. Combined morphological and immunophenotyping examinations confirmed a DLBCL of non-germinal center B-cell origin (Figure 2). Myeloproliferation was significant with nuclear shifted to the right, and red-giant cells hyperplasia was also active, and platelets were aggregately distributed, suggesting no evidence of bone marrow involvement. Consequently, Phase I and International Prognostic Index score 1 was considered. He experienced no taboos in chemotherapy, and completed six cycles of mabthera, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy. Three weeks after the end of chemotherapy, the patient underwent PET/CT scan again, which showed complete remission of the prostatic lesion on CT, with
no active foci in the prostatic lesion on PET (Figure 1C, D), and the SUVmax was 2.0.

**DISCUSSION**

Primary malignant lymphoma arising from the prostate is notably rare, We use PubMed search method, with key words of primary prostatic lymphoma, 87 Articles were retrieved by the end of Jan 2013, approximately 200 cases reported in the world literature. Non-Hodgkin’s lymphoma is the major histological subtype of primary Hodgkin’s lymphoma (PHL) and DLBCL is the most common. Morphology of lymphoma in this case is typical, diffuse infiltrate lymphoid cells in prostate tissue. Immunohistochemical examination showed diffuse expression of CD79a and CD20 in tumor cell, which are the typical characteristics of diffuse large B cell lymphoma. CD3 being negative and diffuse expression of Mum-1 suggested that tumor cell originated from B cells. Moreover, CD30 being negative also tips for non-Hodgkin lymphoma. Negative CK suggesting non epithelial malignancies, combined with negative PSA, exclude the possibility of prostate cancer. Positive bcl-6 indicates the biological activity of lymphoma, the proliferation fraction was 60% with Ki67 antibody. Combining these conditions together, a diagnosis of non germinal center origin of diffuse large B cell lymphoma was made. The three criteria for the diagnosis of primary prostatic lymphoma were as follows: (1) tumor limited to the prostate only; (2) the absence of any other lymphoid node or tissue involvement including blood vessels; and (3) a lymphoma free at an interval of at least 1 mo after diagnosis. Since the clinical symptoms of primary prostatic lymphoma are atypical, including lower urinary tract symptoms, acute urinary retention or hematuria, it is difficult to establish a diagnosis merely based on clinical grounds, which may easily lead to a misdiagnosis as benign prostate hyperplasia or chronic prostatitis. Computerized tomography (CT) and Trans-Rectal UltraSound (TRUS) prostate plays an important role in the location and staging of the primary prostatic lymphoma, it usually manifests as the enlargement of the prostate with low density or hypoechoic lesions with or without abdominal and pelvic enlargement of lymph nodes on CT or US, in addition, CT and TRUS are also of great significance to treatment response to PPL. Gallium scan is optional when distant lymph node involvement was suspected. There were no specific markers for Lymphoma at present, Prostatic Acid Phosphatase May be a sensitive tumor marker protein indicating development and progression of intravascular LBCL, which was a Subtype of diffuse LBCL. Tumor marker like PSA usually is within normal range in most patients. The final diagnosis can be established by surgery or transrectal prostate biopsy.

Because of its rarity, there was no consensus on the optimal treatment of prostatic lymphoma at present. A recent study showed that R-CHOP chemotherapy is superior to CHOP and is the first choice for curative intent,
this combination should be taken into consideration except for prostatic cancer.

The use of FDG PET imaging is uncommon for prostatic lymphoma, and only four cases have been reported in the literature: two cases of mucosa-associated lymphoid tissue lymphoma, revealing mild FDG uptake\(^7\), and two cases of DLBCL, which showed intense hypermetabolism\(^8\). The extent of FDG uptake may be associated with histological types. In our case, the foci of the prostate demonstrated intense FDG uptake, which was similar to the cases reported.

\(^{18}\)F-FDG PET/CT helped diagnose the possibility of PPL in this case, and demonstrated the absence of abnormal hypermetabolic foci in any other nodes or organs. \(^{18}\)F-FDG PET/CT identified significant treatment response after six cycles of chemotheraphy.

In conclusion, \(^{18}\)F-FDG PET/CT is not only a complement to the conventional imaging studies, but also plays a significant role in the diagnosis and treatment of prostatic lymphoma. In short, when a nodal or diffuse uptake is observed in the prostate on PET/CT and PSA is within normal limits, primary prostate lymphoma should be taken into consideration except for prostatic cancer.

**REFERENCES**

1. Masroor HM, Zein-el-Amir MAS, Ashfaq A, Muhammad AF. Incidental primary B-cell lymphoma prostate. JRMC 2011; 15: 127-128
2. Sarris A, Dimopoulos M, Pugh W, Cabanillas F. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol 1995; 153: 1852-1854 [PMID: 7752334 DOI: 10.1016/S0022-5347(01)67330-0]
3. Ghose A, Baxter-Smith DC, Eeles H, Udeshi U, Priestman TJ. Lymphoma of the prostate treated with radiotherapy. Clin Oncol (R Coll Radiol) 1995; 7: 134 [PMID: 7619764 DOI: 10.1016/S0903-6555(05)8018-0]
4. Zauzu JR, Iglesias R, Costa DR, Rincón Mayans A, Brugarolas i Roselló X, Santos AP, Polo JM. Prostatic lymphoma and review of the literature. Actas Urol Esp 2009; 33: 686-690 [PMID: 19711753 DOI: 10.1016/S0210-4806(09)74208-1]
5. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. In: Atlas of Tumor Pathology. Washington DC, Armed Forces Institute of Pathology, 2000: 111-177
6. Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B. Malignant lymphoma involving the prostate: report of 62 cases. Cancer 1998; 83: 732-738 [PMID: 9708938]
7. Jhavar S, Agarwal JP, Naresh KN, Shrivastava SK, Borges AM, Dinshaw KA. Primary extranodal mucosa associated lymphoid tissue (MALT) lymphoma of the prostate. Leuk Lymphoma 2001; 41: 445-449 [PMID: 11378561 DOI: 10.3109/10428190109058003]
8. Lee WC, Chiang PH. Primary Prostate Lymphoma Presented as Urinary Retention in a Young Male Patient: A Case Report. JTUA 2009; 20: 86-88.
9. Mermershtain W, Benharroch D, Lavrenkov K, Geffen DB, German I, Cohen Y. Primary malignant lymphoma of the prostate—a report of three cases. Leuk Lymphoma 2001; 42: 809-811 [PMID: 11697515 DOI: 10.3109/1042819010909345]
10. Seki K, Miyakoshi S, Lee GH, Matsushita H, Mutoh Y, Nakase K, Ida M, Taniguchi H. Prostatic acid phosphatase is a possible tumor marker for intravascular large B-cell lymphoma. Am J Surg Pathol 2004; 28: 1384-1388 [PMID: 15371956 DOI: 10.1016/j.ajsp.2004.02.002]
11. Anca L, Paul R, Bogdan P, Cristina K. R-CHOP VS. CHOP: A cost-effectiveness analysis on Aggressive Non-Hodgkin’s Lymphoma (NHL). Management in health 2009; 2: 18-21.
12. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Feméé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005; 23: 4117-4126 [PMID: 15867204 DOI: 10.1200/JCO.2005.09.131]
13. Csamar J, Kaszás I, Kollár B, Pajor L, Egyházi Z, Fekete S, Egyed M, Timár B. Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathol Oncol Res 2008; 14: 281-284 [PMID: 18493873 DOI: 10.1007/s12252-008-9051-y]
14. Mahawong P, Amornsuvetik T, Soontropa S, Sukpanichnant S. Primary diffuse large B-cell lymphoma of the prostate: A case report. Tai J Surg 2010; 31: 31-34
15. Minamimoto R, Tateishi U, Tomita N, Inayama Y, Omura-Minamisawa M, Tayama Y, Hata M, Kubota Y, Inoue T. F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. Ann Nucl Med 2010; 24: 115-119 [PMID: 20072163]
16. Li G, Dhawan M, Takalkar AM, Lilien DL. FDG PET/CT imaging suggests lymphoma involving prostate may be more resistant to treatment. Clin Nucl Med 2011; 36: 255-257 [PMID: 21285695 DOI: 10.1097/RLU.0b013e31819e012]
17. Hodgson R, Huang YT, Steinké K, Ravi Kumar AS. FDG PET/CT in evaluation and prognostication of primary prostate lymphoma. Clin Nucl Med 2010; 35: 418-420 [PMID: 20479589 DOI: 10.1097/RLU.0b013e3181d46eb7]
